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Autologous transplant for myeloma: when the old meets the 
new
Francesca Gay, Mariella Genuardi and Mario Boccadoro
Survival of multiple myeloma (MM) patients has 
dramatically improved in the last few decades thanks 
to the introduction of several novel agents and to 
improved supportive care strategies. Drugs with different 
mechanisms of action based on disease biology, including 
immunomodulatory (IMIDs) agents, proteasome inhibitors 
(PIs) and, more recently, monoclonal antibodies (MoAbs), 
administered in a total outpatient setting, have proved to 
be highly effective and easily manageable. In this context, 
although autologous transplantation (ASCT) represents a 
major advance and a cornerstone in the treatment of MM, 
the “old” high-dose therapy (HDT) - with the classical 
chemotherapy toxicities (cytopenia, infections, mucositis, 
alopecia) - has become progressively less appealing. The 
continuing and rapid drug development has repeatedly 
questioned the role of upfront ASCT. Novel agent-based 
therapies have been included in the pre-ASCT induction 
and/or post-ASCT consolidation and maintenance, as well 
as evaluated as multidrug combinations in the non-ASCT 
setting. At present, there are four randomized phase III 
trials reporting an improved progression-free survival 
(PFS) with upfront ASCT in comparison with no ASCT 
(Table 1) [1-4]. Despite the expected increase in adverse 
events with HDT and ASCT, toxicities were manageable 
with the current supportive care measures and did not 
translate into an increase in toxic deaths. Interestingly, the 
PFS advantage with ASCT was consistent in most of the 
analyzed subgroups. In two of the four trials, ASCT led 
also to an increase in overall survival (OS). What do these 
results mean in the complex treatment paradigm of MM 
in 2017?
First, it is clear that upfront ASCT still remains the 
standard of care in the context of a sequential approach 
including a pre-transplant induction and a post-transplant 
consolidation/maintenance with novel drugs. Its role has 
been confirmed regardless of the combination evaluated 
as comparator: ASCT led to superior PFS not only when 
compared with oral chemotherapy plus lenalidomide or 
plus bortezomib, but also when the two drugs were used 
in association, with a potentially higher efficacy [1-4]. 
Whether this advantage can be maintained over time 
remains a crucial issue. Data from two trials comparing 
ASCT vs oral chemotherapy plus lenalidomide have 
shown the superiority of ASCT for both PFS and the long-
term endpoints PFS2 and OS; whereas no differences 
in OS between the ASCT and the non-ASCT arms have 
been so far reported in the IFM2009 and EMN02 trials 
[5]. Many factors affect long-term outcome, and treatment 
administered at relapse is certainly a major determinant. 
Of course, the higher the efficacy of the non-transplant 
arm, the lower the survival benefit needed with salvage 
therapy to obtain an OS similar to patients receiving 
upfront ASCT. A pooled analysis of the two lenalidomide-
based trials reported that only 53% of patients treated 
with chemotherapy plus lenalidomide did receive ASCT 
at first relapse, and that the outcome of patients rescued 
with ASCT was superior if compared with the outcome of 
those who received other therapies [5]. Despite a possible 
“selection bias” (patients receiving ASCT at relapse might 
have been in better clinical conditions than patients who 
did not), these results support the role of ASCT also in the 
relapse setting. Of note, in the IFM2009 trial, where up to 
79% of patients treated with lenalidomide plus bortezomib 
upfront were rescued with ASCT at relapse, no differences 
in OS were noticed [3]. Taken together, these two findings 
strengthen the importance of including ASCT in the 
overall treatment strategy of MM patients in 2017. 
Two other relevant points are worth further 
discussion, namely risk stratification and response to 
treatment. These are in fact two important factors to 
define treatment strategy in many cancers. Generally, 
in the setting of curable diseases, low-risk patients may 
be treated with less intensive therapy, whereas high-
risk patients require more intensive regimens. Subgroup 
analyses of all the four trials, despite being based on 
smaller subsets of patients, showed a HR for PFS in favor 
of ASCT (the more intensive treatment) in high-risk but 
also in standard-risk patients [1-4]. In the pooled analysis 
of the two ASCT vs oral chemotherapy plus lenalidomide 
trials, where the advantage of ASCT was evident also 
for PFS2 and OS, the PFS2 and OS benefit was retained 
in both good and bad prognosis patients [5]. Response 
to treatment, and in particular minimal residual disease 
(MRD) negativity, is another important predictor of 
outcome [6]. Data from three of the four trials showed 
that ASCT led to a higher rate of MRD negativity [3,7,8]. 
Moreover, in the IFM 2009 trial, ASCT prolonged PFS 
regardless of MRD status [3]. 
Altogether these data suggest that in 2017 
upfront ASCT is the first choice in all eligible patients, 
independently of patient prognosis and response achieved. 
The higher the efficacy of the combination, the less marked 
the superiority of ASCT, although the PFS advantage with 
ASCT still remains significant. Ongoing and forthcoming 
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trials exploring newer non-transplant combinations 
including second-generation PIs, IMIDs and MoAbs, 
may still challenge the role of upfront ASCT. A better and 
more comprehensive definition of patient prognosis and a 
more sensitive evaluation of MRD should be introduced 
in clinical trials evaluating - in a randomized fashion - 
how to tailor treatment according to patient prognosis and 
response. Results of these trials could change again the 
treatment scenario of MM in the future, hopefully with a 
shift towards a more tailored approach.
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Table 1: Main phase 3 trials with upfront transplantation
Protocol/Treatment schema Median follow-up PFS OS
GIMEMA RV-MM-PI-209 [1]
Rd-MEL200x2 vs Rd-MPR 51.2 months
Median: 43.0 vs 22.4 months 
(HR 0.44; P < 0.001)
4-year: 81.6% vs 65.3% 
(HR 0.55; P = 0.02)
EMN441 [2]
Rd-MEL200x2 vs Rd-CRD 52.0 months
Median: 43.3 vs 28.6 months 
(HR 0.40; P < 0.0001)
4-year: 86% vs 73% 
(HR 0.42; P = 0.004)
IFM2009 [3]
VRD-MEL200-VRD vs VRD 44 vs 43 months
Median: 50 vs 36 months 
(HR 0.65; P < 0.001)
4-year: 81% vs 82%
(HR 1.16; P = 0.87)
EMN02 [4]
VCD-MEL200 vs VCD-VMP 31.6 months
3-year: 65% vs 57.1%
(HR 0.73; P = 0.001)
3-year: 86.3% vs 84.6% 
(HR 0.98; P = 0.899)
 Rd, lenalidomide plus low-dose dexamethasone; MEL200, melphalan 200 mg/m2; MPR, melphalan-prednisone-lenalidomide; 
CRD, cyclophosphamide-lenalidomide-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; VCD, bortezomib-
cyclophosphamide-dexamethasone; VMP, bortezomib-melphalan-prednisone; PFS, progression-free survival; OS, overall 
survival; HR, hazard ratio.
